The Competition Commission of India (CCI) has approved L’Oréal India’s proposed acquisition of 100% of Onesto Labs, the parent company of digital-first personal care platform Innovist. The approval clears a regulatory step for the transaction, which was first announced by L’Oréal in June 2026. Financial details of the deal have not been disclosed.
According to the CCI, the proposed combination involves L’Oréal India acquiring the entire shareholding of Onesto Labs. L’Oréal India, a wholly owned subsidiary of L’Oréal SA, has been operating in India since 1994 and currently has a portfolio of 26 brands, including L’Oréal Paris, Garnier, Maybelline New York and NYX Professional Makeup.
The transaction follows L’Oréal’s June announcement that it would acquire a majority stake in Innovist, a science-led, digital-first Indian personal care company. Onesto Labs was rebranded as Innovist in 2022 and operates as a house-of-brands platform, with products spanning skincare and haircare.
Innovist was founded in 2019 by Rohit Chawla, Sifat Khurana and Vimal Bhola. Its portfolio includes Bare Anatomy, Chemist at Play, SunScoop and Anecdote, with products sold through its own direct-to-consumer channels as well as e-commerce, quick-commerce and offline retail networks across India.
Under the transaction announced in June, Innovist’s founding team is expected to continue running the business as minority shareholders in collaboration with L’Oréal India. The company’s brands will become part of L’Oréal’s Consumer Products Division, bringing the digital-first portfolio into the wider beauty company’s existing business structure.
For L’Oréal India, the acquisition adds a portfolio of Indian personal care brands built around science-led formulations and digital distribution. The company already operates manufacturing facilities in Chakan, Maharashtra, and Baddi, Himachal Pradesh, alongside research and innovation facilities in Mumbai and Bengaluru.
The CCI’s approval comes as L’Oréal continues to expand its presence across India’s beauty and personal care market. The regulator said its detailed order on the transaction would follow.
